• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study
【24h】

Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study

机译：口服血肠球加顺铂，伴随着放射疗法作为III阶段非小细胞肺癌的感应治疗：单臂前瞻性队列研究结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Concurrent chemoradiotherapy (CCRT) is an optimal recommended treatment for stage III non-small cell lung cancer (NSCLC). Herein, we aimed to investigate the efficacy and safety of oral vinorelbine plus cisplatin with concomitant radiotherapy for stage III NSCLC. This prospective, open-label, single-arm, observational cohort study was performed between January 2010 and September 2016. Patients were treated with two?cycles of chemotherapy with 60?mg/m2 intravenous cisplatin on day 1 and 50 mg/m2 oral vinorelbine on days 1, 8, and 15; radiotherapy was administered concurrently from day 1 when chemotherapy was initiated. A total dose of 66-70 Gy radiotherapy was delivered in daily fractions of 2 Gy for 6.5-7 consecutive weeks. The tumor response was assessed after completing concomitant treatment. A total of 58 patients were enrolled and analyzed; 31 patients had stage IIIA NSCLC and 27 had stage IIIB NSCLC. After induction CCRT, 31 patients achieved an objective response (complete response in one and partial response in 30; the response rate was 53.4%). The median progression-free survival was 6.73?months (95% confidence interval [CI], 5.42-7.91), duration of response was 12.30?months (95% CI, 5.59-19.01), and overall survival was 24.83?months (95% CI, 19.26-30.21). No treatment-related mortality was observed, and neutropenia was the most common grade 3 and 4 treatment-related toxicity (11 patients; 18.9%). CCRT with the weekly regimen of oral vinorelbine plus triweekly cisplatin was effective and safe for stage III NSCLC. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：同时进行化学疗法（CCRT）是III阶段非小细胞肺癌（NSCLC）的最佳推荐治疗。在此，我们旨在探讨口服血红素碱加顺铂的疗效和安全性，伴随着III型NSCLC的伴随放射治疗。 2010年1月至2016年9月在2010年1月至9月之间进行了这一前瞻性，开放标签，单臂，观察队员研究。用两次患者治疗患者，在第1天和第50 Mg / M2口服血管内的60℃和50mg / m2静脉内顺铂治疗患者。在第1,8和15天;在开始化疗时，同时给予放射疗法。总剂量为66-70 Gy放射疗法，每天馏分为2 Gy连续6.5-7周。在完成伴随治疗后评估肿瘤反应。共有58名患者注册并分析; 31例患者患有IIIA阶段，27例患有IIIB阶段的NSCLC。诱导CCRT后，31例患者达到客观反应（在30中的一个和部分反应中的完全反应;响应率为53.4％）。中位进展生存率为6.73？月份（95％置信区间[CI]，5.42-7.91），持续时间为12.30？月份（95％CI，5.59-19.01），总生存率为24.83个月（95 ％CI，19.26-30.21）。没有观察到治疗相关的死亡率，中性粒细胞贫症是最常见的3级和4名治疗相关的毒性（11名患者; 18.9％）。 CCRT与口服血管内的每周方案加上三周顺铂，对III阶段有效和安全。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号